Posted by Michael Wonder on 21 Apr 2020
Alk announces Health Canada approval of Itulatek SLIT tablets for the treatment of tree pollen allergy
20 April 2020 - Over 20% of Canadians with allergies are impacted by tree pollen.
Alk today announced that Health Canada has approved once-daily Itulatek (standardised allergen extract, white birch (betula verrucosa) sublingual tablet) for the treatment of tree pollen allergy.
Itulatek, the fourth once-daily sublingual allergy immunotherapy (SLIT) tablet available in Canada from ALK, is indicated as an allergy immunotherapy for the treatment of moderate to severe seasonal allergic rhinitis, with or without conjunctivitis, induced by pollen from birch, alder, and/or hazel in adults 18 to 65 years of age who have a clinical history of symptoms of allergic rhinitis, despite use of symptom-relieving medication, and a positive test of sensitisation to one or more of the pollen of birch, alder, or hazel (skin prick test and/or specific IgE).
